| 15381-7 |
Leishmania braziliensis Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Leishmania brasilensis IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
15381-7 |
|
|
|
|
Both |
|
|
|
0 |
L braziliensis IgM Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; L brasilensis; L brasiliensis; L braziliensis; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 15382-5 |
Leishmania donovani Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Leishmania donovani IgG Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
15382-5 |
|
|
|
|
Both |
|
|
|
0 |
L donovani IgG Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; L donovani; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 15383-3 |
Leishmania donovani Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Leishmania donovani IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
15383-3 |
|
|
|
|
Both |
|
|
|
0 |
L donovani IgM Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; L donovani; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 15384-1 |
Leishmania mexicana Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Leishmania mexicana IgG Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
15384-1 |
|
|
|
|
Both |
|
|
|
0 |
L mexicana IgG Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; L mexicana; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 15385-8 |
Leishmania mexicana Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Leishmania mexicana IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
15385-8 |
|
|
|
|
Both |
|
|
|
0 |
L mexicana IgM Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; L mexicana; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 15386-6 |
Leishmania tropica Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Leishmania tropica IgG Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
15386-6 |
|
|
|
|
Both |
|
|
|
0 |
L tropica IgG Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; L tropica; L tropicalis; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 15387-4 |
Leishmania tropica Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Leishmania tropica IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
15387-4 |
|
|
|
|
Both |
|
|
|
0 |
L tropica IgM Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; L tropica; L tropicalis; Leishmaniasis; Leishmaniosis; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 15388-2 |
Mycoplasma hominis |
PrThr |
XXX |
Pt |
Ord |
Organism specific culture |
|
ACTIVE |
Mycoplasma hominis [Presence] in Specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
15388-2 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
M hominis Spec Ql Cult |
|
|
|
|
|
C&S; Cult; Cultures; ID; Infectious Disease; InfectiousDisease; M hominis; Metamycoplasma hominis; Microbiology; Misc; Miscellaneous; Myco; Mycoplas; Mycoplasm; Mycoplasmosis; Mycoplsm; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 15389-0 |
Parainfluenza virus 1 Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Parainfluenza virus 1 IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
15389-0 |
|
|
|
|
Both |
|
|
|
0 |
HPIV1 IgG Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; HPIV; HPIV1; Human respirovirus 1; i; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Para; Parainflu; Parainfluenza type 1; Parainfluenza type I; PI1; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 1539-6 |
Glucose^4H post 75 g glucose PO |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --4 hours post 75 g glucose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
1539-6 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 4h p 75 g Glc PO SerPl-mCnc |
|
|
|
Y |
|
4h p 75 g Glc PO; 75Gm; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p 75 g Glc PO; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 15390-8 |
Parainfluenza virus 1 Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Parainfluenza virus 1 IgM Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
15390-8 |
|
|
|
|
Both |
|
|
|
0 |
HPIV1 IgM Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; HPIV; HPIV1; Human respirovirus 1; i; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Para; Parainflu; Parainfluenza type 1; Parainfluenza type I; PI1; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 15391-6 |
Parainfluenza virus 1 Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Parainfluenza virus 1 IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
15391-6 |
|
|
|
|
Both |
|
|
|
0 |
HPIV1 IgM Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); HPIV; HPIV1; Human respirovirus 1; i; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Para; Parainflu; Parainfluenza type 1; Parainfluenza type I; PI1; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 15392-4 |
Parainfluenza virus 2 Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Parainfluenza virus 2 IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
15392-4 |
|
|
|
|
Both |
|
|
|
0 |
HPIV2 IgG Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; HPIV; HPIV2; Human rubulavirus 2; ID; II; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Para; Parainflu; Parainfluenza type 2; Parainfluenza type II; PI2; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 15393-2 |
Parainfluenza virus 2 Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Parainfluenza virus 2 IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
15393-2 |
|
|
|
|
Both |
|
|
|
0 |
HPIV2 IgM Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); HPIV; HPIV2; Human rubulavirus 2; ID; II; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Para; Parainflu; Parainfluenza type 2; Parainfluenza type II; PI2; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 15394-0 |
Parainfluenza virus 3 Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Parainfluenza virus 3 IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
15394-0 |
|
|
|
|
Both |
|
|
|
0 |
HPIV3 IgG Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; HPIV; HPIV3; Human respirovirus 3; ID; III; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Para; Parainflu; Parainfluenza type 3; Parainfluenza type III; PI3; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 15395-7 |
Parainfluenza virus 3 Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Parainfluenza virus 3 IgM Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
15395-7 |
|
|
|
|
Both |
|
|
|
0 |
HPIV3 IgM Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; HPIV; HPIV3; Human respirovirus 3; ID; III; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Para; Parainflu; Parainfluenza type 3; Parainfluenza type III; PI3; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 15396-5 |
Toxoplasma sp Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Toxoplasma gondii IgG Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
15396-5 |
|
|
|
|
Both |
|
|
|
0 |
Deprecated Toxoplasma IgG Ser-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; species; spp; SR; Toxo; Toxoplasmosis |
2.69 |
1.0k |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 15397-3 |
Trypanosoma cruzi Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Trypanosoma cruzi IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
15397-3 |
|
|
|
|
Both |
|
|
|
0 |
T cruzi IgM Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Chagas disease; Dilution factor; Dilution Factor (Titer); ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; T cruzi; Titer; Titered; Titre; Trypanosomiasis; Trypanosomosis; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 15398-1 |
Neuronal nuclear Ab |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Neuronal nuclear Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
15398-1 |
|
|
|
|
Both |
|
|
|
0 |
Hu Ab Titr Ser |
|
|
|
Y |
|
ABS; Aby; ANA; ANF; ANNA; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); Hu; NA; Neuro; Neurology; Nuc; Oncology; Point in time; Random; Serology; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 15399-9 |
Neuronal nuclear Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
IF |
|
ACTIVE |
Neuronal nuclear IgG Ab [Units/volume] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
15399-9 |
|
IF |
|
|
Both |
|
|
|
0 |
Hu IgG Ser IF-aCnc |
|
|
|
Y |
|
ABS; Aby; ACIF; ANA; ANA IgG; ANF; ANNA; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Antinuclear antibody; Arbitrary concentration; Autoantibodies; Autoantibody; FA; FANA; Fluorescent antibody; Fluoresent; Hu; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; NA; Neuro; Neurology; Nuc; Oncology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR; Time Resolved Fluorescence; TRF |
2.69 |
1.0k |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 154-5 |
Cephaloglycin |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Cephaloglycin [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
154-5 |
|
Agar diffusion |
|
|
Observation |
|
|
|
0 |
Cephaloglycin Islt KB |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 1540-4 |
Glucose^5H post 100 g glucose PO |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --5 hours post 100 g glucose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
1540-4 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 5h p 100 g Glc PO SerPl-mCnc |
|
|
|
Y |
|
5h p 100 g Glc PO; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p 100 g Glc PO; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 15400-5 |
Platelet Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Platelet IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
15400-5 |
|
|
|
|
Both |
|
|
|
0 |
Platelet IgG Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Circulating platelet ab; Hematology; Heme; Immune globulin G; Immunoglobulin G; Ordinal; Pl; Platelet ab.free; Platelet auto-antibodies; Platelets; Platelt; Plt; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR; Thrombocyte; Thrombocytes |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 15401-3 |
Drugs |
Prid |
Bld |
Pt |
Nom |
Screen |
|
ACTIVE |
Drugs identified in Blood by Screen method Nominal |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
15401-3 |
|
Screen |
|
|
Both |
|
|
|
0 |
Drugs Bld Scn Nom |
|
|
|
|
|
Blood; Drug; DRUG/TOXICOLOGY; Drugs; Identity or presence; Nominal; Point in time; Random; Scn; Scr; Scrn; WB; Whole blood |
2.79 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 15402-1 |
Ethanol |
PrThr |
Meconium |
Pt |
Ord |
|
|
ACTIVE |
Ethanol [Presence] in Meconium |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
15402-1 |
|
|
|
|
Both |
|
|
|
0 |
Ethanol Mec Ql |
|
|
|
|
|
Alc; Alcohol; DRUG/TOXICOLOGY; Drugs; Ethyl alcohol; EtOH; Mec; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
